+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
ZYDUSWELL

Share Price

 

 

Performance

  • Today's Low
  • ₹500
  • Today's High
  • ₹510
  • 52 Week Low
  • ₹368
  • 52 Week High
  • ₹552
  • Open Price₹503
  • Previous Close₹503
  • Volume112,263
  • 50 DMA₹483.38
  • 100 DMA₹465.39
  • 200 DMA₹446.80

Chart

Smart Investing Starts Here Start SIP with for Steady Growth!

Invest Now

Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 81.1
  • PEG Ratio
  • -1.9
  • Market Cap Cr
  • 15,991
  • P/B Ratio
  • 2.8
  • Average True Range
  • 19.75
  • EPS
  • 7.3
  • Dividend Yield
  • 0.2
  • MACD Signal
  • 3.45
  • RSI
  • 53.6
  • MFI
  • 42.35

Latest Stock News Updates

New launches, India business growth key triggers for Zydus Lifesciences

Strong domestic growth, an expanding specialty portfolio, acquisitions and a robust product pipeline are expected to support Zydus Lifesciences' performance in FY27

Zydus Lifesciences up 2% to 52-wk high on USFDA review nod, buyback tweak

The pharmaceutical company said the buyback price has been increased from 1,150 per equity share to 1,260 per equity share

Zydus Hospitals, Gujarat crosses 1000 Robotic Joint Replacement Surgeries across centers in less than a year

Financials

Technicals

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Zydus Wellness Ltd. is a leading health and wellness company in India, offering a range of products including sugar substitutes, nutraceuticals, and skincare under brands like Sugar Free, Complan, and Everyuth, promoting healthier lifestyle choices.

Zydus Wellness has an operating revenue of Rs. 3,961.00 Cr. on a trailing 12-month basis. An annual revenue growth of 46% is outstanding, Pre-tax margin of 6% is okay, ROE of 3% is fair but needs improvement. The company has a debt to equity of 52%, which is bit higher. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 10% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 9% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 30 which is a POOR score indicating inconsistency in earnings, a RS Rating of 85 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 59 indicates it belongs to a fair industry group of Food-Misc Preparation and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-18 Audited Results & Final Dividend
2026-02-03 Quarterly Results
2025-11-05 Quarterly Results
2025-07-30 Quarterly Results
2025-05-19 Audited Results, Dividend & Stock Split
Date Purpose Remarks
2025-07-11 FINAL Rs.6.00 per share(60%)Final Dividend
2024-07-19 FINAL Rs.5.00 per share(50%)Final Dividend
2023-07-21 FINAL Rs.5.00 per share(50%)Final Dividend
2022-07-15 FINAL Rs.5.00 per share(50%)Final Dividend
View Dividend History Arrow
Date Purpose Remarks
2025-09-18 Split Rs.0.00 split from Rs. 10/- to Rs. 2/-.

Shareholding Pattern

69.63%
18.43%
0.39%
3.17%
0%
6.47%
1.91%

FAQs

share price is ₹502 As on 04 June, 2026 | 13:22

The Market Cap of is ₹15990.8 Cr As on 04 June, 2026 | 13:22

The P/E ratio of is 81.1 As on 04 June, 2026 | 13:22

The PB ratio of is 2.8 As on 04 June, 2026 | 13:22

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23